First center for clinical trail of Contezolid tablets in pediatric patients with complicated Skin and Soft Tissue Infections has started

On April 12, 2023, Shanghai MicuRx Pharmaceuticals Co., Ltd. (stock code: 688373.SH) announced the initiation of the first center for the clinical trial of Contezolid tablets in pediatric patients with complicated Skin and Soft Tissue Infections.

On October 26, 2022, MicuRx obtained the approval notice for supplementary application of drug clinical trials from the National Medical Products Administration, allowing the expansion of Contezolid tablets’ indications to pediatric patients with complicated skin and soft tissue infections.

Contezolid tablets is a new generation of azole antibacterial drugs independently designed and developed by MicuRx Pharmaceutical. They are used for the treatment of infections caused by multidrug-resistant Gram-positive bacteria. It is reported that Contezolid tablets have implemented several pioneering measures in clinical trials of antibacterial drugs in China, setting industry benchmarks for clinical trials in the field of innovative antimicrobial drugs. The success of Contezolid tablets in clinical trials in China has laid a solid foundation for elevating clinical trial standards and improving product quality in the future development of innovative antimicrobial drugs in China.

By the end of 2022, Contezolid tablets had covered 309 hospitals in 50 cities nationwide, with formal access and bulk procurement in over 70 hospitals. Hospital channel sales accounted for approximately 53% of the total. In 2022, Contezolid tablets achieved an annual revenue of 48.2 million RMB, a year-on-year increase of 529%.

This clinical trial will be jointly led by Professor Ma Lin, Professor Liu Gang from Beijing Children’s Hospital affiliated to Capital Medical University, and Professor Zhang Jing from Huashan Hospital affiliated to Fudan University. They will serve as the leading principal investigators (PIs). Professor Ma Lin is a renowned expert in pediatric dermatology at Beijing Children’s Hospital affiliated to Capital Medical University and the Associate Director of the Department of Dermatology and Venereology at Capital Medical University. In addition, she holds various positions, including Chair of the Pediatric Dermatology Subspecialty Committee of the Chinese Physician Association Dermatology Branch. Professor Liu Gang is the Director of the Department of Infectious Diseases at Beijing Children’s Hospital and also holds positions such as Executive Committee Member of the Asia-Pacific Pediatric Infectious Diseases Expert Committee and Chair of the Infection Specialty Committee at Futang Research Center of Pediatric Development. Professor Zhang Jing is the Deputy Director of the Antibiotics Research Institute at Huashan Hospital affiliated to Fudan University and the Director of Phase I Clinical Research. She also holds positions such as Deputy Chair of the Chemotherapy Pharmacology Professional Committee of the Chinese Pharmacological Society.